IL-17: a new actor in IFN-driven systemic autoimmune diseases

Area of Science:

• Immunology
• Autoimmune Diseases

Background:

• Systemic autoimmune diseases, including lupus erythematosus, are characterized by type I interferon-driven immune responses.
• Exaggerated B-cell activation and autoantibody production are hallmarks of these conditions.
• Th17 cells, a subset of T-helper cells, are known for their potent inflammatory capabilities.

Purpose of the Study:

• To review emerging evidence on the role of IL-17 and IL-17-producing cells in type I interferon-driven systemic autoimmune diseases.
• To explore potential mechanisms by which these cells contribute to disease pathogenesis.
• To discuss the synergistic interaction between type I interferon and IL-17 in autoimmune diseases.

Main Methods:

• Literature review of studies in humans and animal models.
• Analysis of existing research on IL-17 and Th17 cells in systemic autoimmune diseases.
• Discussion of proposed pathogenic mechanisms.

Main Results:

• Growing evidence suggests a role for IL-17 and IL-17-producing cells in the pathogenesis of systemic autoimmune diseases like lupus.
• Studies in both human patients and animal models indicate this involvement.
• Potential mechanisms for IL-17's contribution to disease are being investigated.

Conclusions:

• IL-17 and IL-17-producing cells, including Th17 cells, are implicated in the development of type I interferon-driven systemic autoimmune diseases.
• Type I interferon and IL-17 may act in concert to amplify autoimmune and inflammatory responses.
• This combined action presents a significant factor in the pathogenesis of these diseases.